Table 2.
Baseline characteristics of a relapser after 8 weeks of glecaprevir/pibrentasvir.
| Characteristics | A Relapser at Week 12 after Treatment |
|---|---|
| Age (years) | 65 |
| Gender | Male |
| Interferon | Naive |
| Interferon-free DAAs | Naive |
| HCV genotypes | 1b |
| Pretreatment HCV RNA (LIU/mL) | 5.4 |
| Body weight (kg) | 51 |
| Body length (m) | 1.58 |
| History of HCC | No |
| Chronic hepatitis or cirrhosis | Chronic hepatitis |
| Liver stiffness (kPa) | 7.9 |
| AST (IU/L) | 91 |
| ALT (IU/L) | 80 |
| Hemoglobin (g/dL) | 14.1 |
| Platelets (×104/μL) | 23.8 |
| eGFR (mL/min/1.73 m2) | 64.4 |
| Adherence > 80% | Yes |
| * NS5A-L31 | Wild |
| * NS5A-Y93 | Wild |
DAA, direct-acting antivirals; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate. * Resistance-associated substitutions (NS5A-L31 and Y93) after treatment-relapse were determined by direct-sequence methods.